Literature DB >> 18810196

Genesis and biology of vestibular schwannomas.

Pierre-Hugues Roche1, Corinne Bouvier, Olivier Chinot, Dominique Figarella-Branger.   

Abstract

This review chapter is a synthesis of the recent literature about pathogenesis of schwannomas with emphasis on vestibular schwannomas (VSs). The cornerstone of cellular transformation and proliferation of Schwann cells toward schwannomas has been attributed to the nonexpression of normal schwannomin/merlin (S/M) by these cells. The understanding of this mechanism has been gained from molecular genetic studies of neurofibromatosis type 2 (NF2) patients, in whom mutations of a tumor suppressor gene (NF2 gene) was clearly identified. S/M is the normal NF2 gene product. Lack of normal S/M protein in the schwannoma cell is due to gene mutation in 50% of sporadic VSs. In the other cases, epigenetic factors or activation of protease cascade contribute to ineffective S/M. The exact interactions of S/M with extracellular matrix, membranous glycoprotein and cytoskeleton are not fully understood. However, it is recognized that these interactions activate several pathways that might regulate cell-cycle process, apoptosis and intercellular interaction. Apart from the involvement of the S/M pathway, the authors review the potential role of other genetic abnormalities and growing factors that are supposed to be involved in the pathogenesis of VS. Understanding the pathways of action and regulation of S/M may provide the basics for identifying potential therapeutic targets, which is of paramount importance for a better management of NF2 patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18810196     DOI: 10.1159/000156556

Source DB:  PubMed          Journal:  Prog Neurol Surg        ISSN: 0079-6492


  8 in total

Review 1.  Merlin: a tumour suppressor with functions at the cell cortex and in the nucleus.

Authors:  Wei Li; Jonathan Cooper; Matthias A Karajannis; Filippo G Giancotti
Journal:  EMBO Rep       Date:  2012-03       Impact factor: 8.807

2.  Vestibular assessment in patients with vestibular schwannomas: what really matters?

Authors:  R Teggi; A Franzin; G Spatola; N Boari; P Picozzi; M Bailo; L O Piccioni; F Gagliardi; P Mortini; M Bussi
Journal:  Acta Otorhinolaryngol Ital       Date:  2014-04       Impact factor: 2.124

3.  What is the site of origin of cochleovestibular schwannomas?

Authors:  Christof Roosli; Fred H Linthicum; Sebahattin Cureoglu; Saumil N Merchant
Journal:  Audiol Neurootol       Date:  2011-09-29       Impact factor: 1.854

4.  Gynaecological Perspective of Schwannoma: A Rare Pelvic Tumour.

Authors:  Neranjana Padmanaban; Priya Subash Chandrabose; Muthuvel Esakki; Hephzibah Kirubamani; Chitra Srinivasan
Journal:  J Clin Diagn Res       Date:  2016-04-01

5.  Rac1 controls Schwann cell myelination through cAMP and NF2/merlin.

Authors:  Li Guo; Chandra Moon; Karen Niehaus; Yi Zheng; Nancy Ratner
Journal:  J Neurosci       Date:  2012-11-28       Impact factor: 6.167

6.  Axillary schwannoma, preoperative diagnosis on a tru-cut biopsy: Case report and literature review.

Authors:  Hager Aref; Georges A Abizeid
Journal:  Int J Surg Case Rep       Date:  2018-09-29

Review 7.  Proton and Heavy Particle Intracranial Radiosurgery.

Authors:  Eric J Lehrer; Arpan V Prabhu; Kunal K Sindhu; Stanislav Lazarev; Henry Ruiz-Garcia; Jennifer L Peterson; Chris Beltran; Keith Furutani; David Schlesinger; Jason P Sheehan; Daniel M Trifiletti
Journal:  Biomedicines       Date:  2021-01-03

8.  Phase 0 Clinical Trial of Everolimus in Patients with Vestibular Schwannoma or Meningioma.

Authors:  Matthias A Karajannis; Audrey Mauguen; Ekrem Maloku; Qingwen Xu; Erin M Dunbar; Scott R Plotkin; Anna Yaffee; Shiyang Wang; J Thomas Roland; Chandranath Sen; Dimitris G Placantonakis; John G Golfinos; Jeffrey C Allen; Nicholas A Vitanza; Luis A Chiriboga; Robert J Schneider; Jingjing Deng; Thomas A Neubert; Judith D Goldberg; David Zagzag; Filippo G Giancotti; Jaishri O Blakeley
Journal:  Mol Cancer Ther       Date:  2021-06-17       Impact factor: 6.261

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.